Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.
about
A blood-brain barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD)A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") miceCircadian dysfunction may be a key component of the non-motor symptoms of Parkinson's disease: insights from a transgenic mouse modelVocalization deficits in mice over-expressing alpha-synuclein, a model of pre-manifest Parkinson's disease.Behavioral genetic contributions to the study of addiction-related amphetamine effects.Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease.Strengths and limitations of genetic mouse models of Parkinson's disease.Modulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies--is the juice worth the squeeze?Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein.Rationale for therapeutic silencing of alpha-synuclein in Parkinson's diseaseBehavioral phenotyping of mouse models of Parkinson's disease.The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's diseaseChronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons.Tau reduction does not prevent motor deficits in two mouse models of Parkinson's diseaseNeurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease.Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein.A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.Impairment of mitochondria in adult mouse brain overexpressing predominantly full-length, N-terminally acetylated human α-synucleinBehavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expressionEffects of antioxidants on cancer prevention and neuromotor performance in Atm deficient mice.Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein.Olfactory deficits in mice overexpressing human wildtype alpha-synuclein.Analysis of striatal transcriptome in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neuronsDifferential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.Mannose 6-Phosphate Receptor Is Reduced in -Synuclein Overexpressing Models of Parkinsons Disease.Animal models of the non-motor features of Parkinson's disease.Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice.Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synucleinAxonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synucleinAtp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits.Molecular pathogenesis, experimental models and new therapeutic strategies for Parkinson's disease.Animal models of Parkinson's disease progressionIn vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?Mice overexpressing wild-type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation.Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein.A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's ResearchWIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.In vivo electrophysiology of nigral and thalamic neurons in alpha-synuclein-overexpressing mice highlights differences from toxin-based models of parkinsonism.Cognitive deficits in a mouse model of pre-manifest Parkinson's diseaseParkinson's disease mouse models in translational research.
P2860
Q24612655-66D37F20-BD35-4D08-A8A1-71CAD4582523Q26859072-DC9B3293-5634-4AFF-9B97-556C8D01270EQ28384426-82AB2B1D-6677-49FB-9D98-63AD4E86B49DQ30415147-E279D7D7-FB05-4ABC-A841-A52D432653B1Q30494693-66FCCA5E-FB03-4703-9660-0DEB2C3CE342Q30512976-D51720C9-D996-4060-9F14-597E622D8634Q33347250-7714B38C-5945-4FA6-90DC-36166669F271Q33392127-D1DA6B92-99D3-473F-A364-2A99DEF084BFQ33577056-32399B30-4561-473B-B31A-A76566FAC9EAQ33636374-67FA97C0-6689-435B-96C3-5E562DC403C2Q33820609-68D39DD9-F7AB-4736-BBBE-651986A510DEQ33850971-1DFD7DB2-494F-4BA9-BE75-1C6002586950Q34056025-EE3FB84B-365B-4367-BE58-A7DDF44CF350Q34113712-229DCF95-E7A1-435A-B2A5-67FAB4F4238AQ34181738-B804C2C0-DDD4-40CE-A587-28FC63B90708Q34292532-03486893-BD10-4078-85AE-F8CCA431A698Q34612993-87999350-F8D1-44D3-8314-35E25FEE43C3Q34718257-E2622C49-C906-457F-BC5F-167FAED59667Q34991077-4F618F99-3ACC-428D-8B0D-7A7FB4BD0218Q35021217-14361051-1251-443C-8BC9-9E709B5D08C3Q35025891-52A27508-9AC0-448D-B8F2-DFDFF032F3AEQ35026044-5FA46BB8-F26F-46E2-AD60-5E5970E3B8CAQ35728813-9906A194-8DF3-4A94-8ADA-D796997A4B1DQ35922870-11D45934-FF84-48CC-87E8-951C94E9892BQ36100354-C9CBC8F8-DC2E-4350-BFD6-059316FCCD04Q36235578-CF63D114-088B-4D98-B408-38C25550EEA6Q36265332-6087C52A-CB15-4278-AAFC-D5F9FFF1AEF1Q36585297-0C04A630-4CA7-48E7-8D69-8F34BA392DF7Q36658992-C210419E-D3D3-464F-92FB-BC8A3F8DEAD1Q36787223-C499DE42-2678-4F4B-B4B0-78D4F4179DFEQ36883776-2C1B2672-E9D9-4609-9014-47CDAF2FEC34Q36924624-55C09BEA-BA03-4C72-836F-5DA1ED619485Q36976137-C4854A4A-9C31-4E0C-A1B6-AAD4A1C881C7Q37016812-91DB18D0-6286-4677-A5BE-F27A2CFFA06FQ37161459-1E96ED57-F405-4B4B-84A8-257C151F3F2DQ37287403-A69993FD-671A-40D0-A4E4-75D7E8FE37FEQ37371387-EF9AAC57-BF81-4538-B601-AC15B403DB7AQ37441397-86C4D030-FCF5-4251-86D5-E4E9DE5EBBC5Q37669038-FA3F6B89-E3ED-42DB-BDDD-9D70FB8126EEQ37874160-8F137507-0001-42DA-968E-1507646FF1F7
P2860
Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Behavioral effects of dopamine ...... uman wildtype alpha-synuclein.
@ast
Behavioral effects of dopamine ...... uman wildtype alpha-synuclein.
@en
type
label
Behavioral effects of dopamine ...... uman wildtype alpha-synuclein.
@ast
Behavioral effects of dopamine ...... uman wildtype alpha-synuclein.
@en
prefLabel
Behavioral effects of dopamine ...... uman wildtype alpha-synuclein.
@ast
Behavioral effects of dopamine ...... uman wildtype alpha-synuclein.
@en
P2093
P2860
P921
P1433
P1476
Behavioral effects of dopamine ...... uman wildtype alpha-synuclein.
@en
P2093
C B Hutson
E Rockenstein
M S Levine
M-F Chesselet
S M Fleming
P2860
P304
P356
10.1016/J.NEUROSCIENCE.2006.07.005
P407
P577
2006-08-23T00:00:00Z